A Phase 1 interventional study of HRS-5965 and Placebo in Glomerulonephritis, sponsored by Chengdu Suncadia Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-23.
Sponsored by Chengdu Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Glomerulonephritis with a site in China — 7 open to participants now, 12 under way, 5 of them phase 3. Glomerulonephritis · China.
Among the 24 studies in Glomerulonephritis with a site in China, this one is the 8th largest by enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2022, is one of 2 in phase 1, and was the 13th registered.
115 studies on the registry are indexed under Glomerulonephritis; 32 are open to participants now.
Browse Glomerulonephritis studies →7 of the 24 studies in Glomerulonephritis with a site in China are open now. Recruiting first, the newest first:
AstraZeneca · Sites in China
Ages 18+
Novartis Pharmaceuticals · Sites in China, United States, Colombia and 5 more countries
Ages 2–18
Kira Pharmacenticals (US), LLC. · Sites in China
Ages 18–75
Zhujiang Hospital · Sites in China
Ages 15–79
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 26 Glomerulonephritis studies recruiting now, 15 (58%) set no upper age limit and 6 (23%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 83 is above the median of 50 across 87 interventional studies indexed under Glomerulonephritis.
Median enrollment 74 across the 18 interventional studies, 650 across the 6 observational. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 24 have an industry lead sponsor. The 10 most frequent:
This study is registered under Chengdu Suncadia Medicine Co., Ltd., one of the names counted as Jiangsu HengRui Medicine Co., Ltd.. Under that name alone:
Chengdu Suncadia Medicine Co., Ltd. is the lead sponsor of 24 studies on the registry; 8 are open to participants now.
Jiangsu HengRui Medicine Co., Ltd. has 1 study filed under Glomerulonephritis — fewer than ten, so there is no comparison to draw.
3 of the studies in Glomerulonephritis with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
| NCT07330362Zhujiang HospitalThe Clinical Application of Artificial Intelligence Assisted Renal Biopsy Diagnosis System. | 2026-12-31 |
| NCT07111338Peking University First HospitalTelitacicept for PGNMID: A Single-Arm Study | 2027-05-29 |
Add all 3 to your calendar (.ics) → With an account.
Among the 24 studies in Glomerulonephritis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The trial is the first human trial. The safety, tolerability, PK and PD of HRS-5965 tablets will be evaluated in healthy subjects and subjects with impaired renal function. The study was divided into three parts:
Part 1: single ascending dose, randomized, double-blind study,with 6 dose groups preset, of which 1 group will be administered under fasted and fed conditions; Part 2: Multiple ascending dose, randomized, double-blind study,with 4 dose groups preset; Part 3: an open-label, nonrandomized, single-dose study to evaluate the effect of severe renal impairment (RI) on the safety, tolerability, pharmacokinetics, and pharmacodynamics of HRS -5965 compared to demographically-matched healthy participants with normal renal function.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Study on subjects with renal insufficiency
Exclusion Criteria:
Study on subjects with renal insufficiency
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
single ascending dose, randomized, double-blind study,with 6 dose groups preset, of which 1 group will be administered under fasted and fed conditions. The food impact study consisted of 10 subjects, 8 of whom received HRS-5965 tablets and 2 of whom received placebo. The remaining cohorts required 8 subjects each, with 6 receiving HRS-5965 tablets and 2 receiving placebo.
Drug: HRS-5965 · Drug: Placebo
Multiple ascending dose, randomized, double-blind study,with 4 dose groups preset; Each dose group consisted of 8 healthy adult subjects randomly assigned 6:2 to HRS-5965 tablets or placebo.
Drug: HRS-5965 · Drug: Placebo
an open-label, nonrandomized, single-dose study to evaluate the effect of severe renal impairment (RI) on the safety, tolerability, pharmacokinetics, and pharmacodynamics of HRS -5965 compared to demographically-matched healthy participants with normal renal function. Subjects took HRS5965 tablets.
Drug: HRS-5965
Subjects took HRS5965 tablets in Part 1, Part 2 and Part 3.
Subjects took Placebo in Part 1 and Part 2.
The incidence and severity of adverse events to assess safety and tolerability
Time frame: up to 24 days
Area under the plasma concentration versus time curve (AUC) on Day 1 for Part 1 and Part 3
Time frame: Pre-dose to 144 hours post-dose
Peak plasma concentration (Cmax) on Day 1 for Part 1 and Part 3
Time frame: Pre-dose to 144 hours post-dose
Time to maximum plasma concentration (Tmax) on Day 1 for Part 1 and Part 3
Time frame: Pre-dose to 144 hours post-dose
• Area under the plasma concentration versus time curve (AUC) on Day 1 and Day 10 for Part 2
Time frame: Pre-dose to 144 hours post-dose
Peak plasma concentration (Cmax) on Day 1 and Day 10 for Part 2
Time frame: Pre-dose to 144 hours post-dose
Time to maximum plasma concentration (Tmax) on Day 1 and Day 10 for Part 2
Time frame: Pre-dose to 144 hours post-dose
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Oct 2022 to primary completion in Nov 2023, 12 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HRS-5965
Chengdu Suncadia Medicine Co., Ltd. →